1[1]CIBIS-Ⅱ Investigators and committees the. cardiac insufficiency bisoprolol study Ⅱ(CIBIS-Ⅱ):a randomized trial[J]. Lancet,1999,353:9-13.
2[2]MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL randomized intervention trial in congestive heart failure(MERIT-HF)[J]. Lancet,1999,353:2001.
3[3]Krum H,Whorlow S. Meta-Analysis of effect of beta-blocker therapy on mortality on NYHA class Ⅳ CHF patients[J]. Circulation(Sepplement 1),1999,100(18):I-208.
4[4]Packer M. COPERNICUS(Carvedilol prospective randomiged cumulative survival):Evaluates the effects of carvedilol top-of ACE on major cardiac events in patients with heart failure NYHAⅡ～ⅣⅩⅩⅡ congress of the europeau society of cardillgy[C], 2000. Aug26～30. Hot-line symposium.
5[5]Zannad F,Perez A,Pitt B,et al. Mechanisms contributing to the survival benefit with aldosterone antagonist therapy in heart failure. Effects on neurohormones and cardiac fibrosis:a substudy of RALES[J]. Eur Heart J,2000,21(Abstract Supplement):22.
6[6]Guazzi M,Pontone G,Agostonip P,et al. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure[J]. Am J Cardiol,1999,84(9):1038-1043.
7[7]Milfred-LaForest SK,Shubert J,Mendoza B,et al. Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and oral angiotensin-converting enzyme inhibitors[J]. Am J Cardiol,1999,84:894-899.
8[8]O'Connor CM,Gattis WA,Uretshy BF,et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure:Insights from the flolan international randomized survival trial(FIRST)[J]. Am Heart J,1999,138(1):78-85.
9[9]Kukin ML,Frendenberger RS,Mannino MM,et al. Short-term and long-term hemnondynamic and clinical effects of metroprolol alone and combined with amlodipine in patients with chronic heart failure[J]. Am Heart J, 1999,138,261-268.
10[10]Consin J,Diez J,Effects of type of diuretic on mortality in patients with chronic congestive heart failure. European Heart J,2000,21(Abstract Supplement):296.
同被引文献18
1臧益民 臧伟进 朱妙章.心脏与内分泌.心脏杂志,2001,13(6):557-563.
2Steering Committee and membershipof the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensusrecommendation for the management of chronic heart failure[J]. Am JCardiol,1999,83:2A-38A.
3Schrier R,Abraham W. Hormones and hemodynamics in heart failure[J]. N Engl JMed,1999,341:577-585.
4Packer M,Bristow M,Cohn J,et al. The effect of carvedilol on morbidity andmortality in patients with chronic heart faulure[J]. N Engl J Med,1996,334:1349-1355.
5MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heartfailure:Metoprolol CR/XL Randomized Intervention Trial in Congestive HeartFailure(MERIT-HF)[J]. Lancet,1999,353:2001-2007.
6Hjalmarson A,Goldstein S,Fagerberg B,et al. Effects of controlled-releasemetoprolol on total mortality,hospitalizations,and well-being in patients with heartfailure:the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure(MERIT-HF)[J]. JAMA,2000,283:1295-1302.
7CIBIS-Ⅱ investigators and committees. The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBIS-Ⅱ):a randomized trial[J]. Lancet,1999,353:9-13.
8Cardinale V,Chi J. Drug Topics red book[M]. Montvale,NJ:Medical Economics,1999.
9Bleske BE,Glibert EM,Munger MA. Carvedilol:therapeutic application and practiceguidelines[J]. Pharmacotherapy,1998,18:729-737.
10Bonet S,Agusti A,Arnau JM,et al. Beta-adrenergic blocking agents in heartfailure:benefits of vasodilating and non-vasodilating agents according to patients′characteristics:a meta-analysis of clinical trails[J]. Arch Intern Med,2000,160:621-627.
